Last edition
News about "Novo Nordisk"
Novo Nordisk and AWS Partner to Accelerate AI-Driven Drug Discovery
Novo Nordisk and AWS are partnering to accelerate AI-driven drug discovery, with a new London AI hub and AWS becoming Novo Nordisk’s preferred cloud provider.
Novo Nordisk | 12/08/2026 | By News Bureau
Dutch Court Orders Halt to Sale of Compounded Semaglutide Nasal Spray in Victory for Novo Nordisk
The Hague court rules in favour of Novo Nordisk, stopping the sale of an unapproved compounded semaglutide nasal spray and strengthening safeguards for pharmaceutical innovation and patient safety.
Novo Nordisk | 07/08/2026 | By News Bureau | 105
Novo Nordisk Provides Phase 3 ZEUS Trial Update
Novo Nordisk shared an update on the phase 3 ZEUS trial evaluating patients with ASCVD, CKD and inflammation enrolled in a placebo-controlled study.
Novo Nordisk | 03/08/2026 | By News Bureau | 230
Emcure Receives CDSCO Nod to Expand Poviztra's Use for MASH Indication
Emcure has received CDSCO approval to expand Poviztra's use for non-cirrhotic metabolic dysfunction-associated steatohepatitis (MASH), addressing a major unmet need in progressive liver disease treatment.
Novo Nordisk | 21/07/2026 | By News Bureau
FRONTIER4 extension study demonstrates sustained safety, low bleeding rates and flexible dosing across children, adolescents and adults, while new data on concizumab highlights reduced bleeding episodes in pediatric patients with hemophilia.
Novo Nordisk | 13/07/2026 | By News Bureau | 121
Vivani Medical has entered into an agreement with Novo Nordisk to evaluate NPM-139, its ultra long-acting semaglutide implant for chronic weight management. The implant aims to offer a convenient once- or twice-yearly treatment option, with Phase 1 clinical trials expected to commence in mid-2026.
Novo Nordisk | 09/07/2026 | By News Bureau
UK MHRA Approves Wegovy for Treatment of MASH in Adults with Liver Fibrosis
The UK's Medicines and Healthcare products Regulatory Agency has conditionally approved Novo Nordisk's Wegovy (semaglutide) for treating metabolic-associated steatohepatitis (MASH) in adults with moderate-to-advanced liver fibrosis, subject to ongoing confirmatory clinical data.
Novo Nordisk | 06/07/2026 | By News Bureau
Shantha Biologics Announces Strategic Cartridge Fill-Finish Collaboration
Shantha Biologics has announced a cartridge fill-finish collaboration with Novo Nordisk, strengthening high-quality biologics manufacturing and global healthcare partnerships.
Novo Nordisk | 04/07/2026 | By News Bureau
Wegovy Pill Prescriptions Surpass 3 Million as Novo Nordisk Presents New ADA 2026 Data
Novo Nordisk announced that Wegovy pill prescriptions have surpassed 3 million since launch, marking one of the largest US pharmaceutical launches by volume. Most prescriptions are from people new to GLP-1 therapy, expanding access to obesity treatment, while new clinical analyses are being presented at ADA 2026.
Novo Nordisk | 10/06/2026 | By News Bureau | 558
Novo Nordisk's Zenagamtide Delivers Up to 14.6 Percent Weight Loss in Type 2 Diabetes
Novo Nordisk’s investigational once-weekly therapy zenagamtide demonstrated significant A1C reductions and up to 14.6 percent weight loss in adults with Type 2 Diabetes in a phase 2 trial presented at ADA 2026. The strong results support advancement of zenagamtide into phase 3 clinical development.
Novo Nordisk | 08/06/2026 | By News Bureau | 156
We use our own and third party cookies to produce statistical information and show you personalized advertising by analyzing your browsing, according to our COOKIES POLICY. If you continue visiting our Site, you accept its use.
More information: Privacy Policy